170 filings
Page 3 of 9
8-K
k5qd2c
2 Apr 21
Other Events
5:00pm
8-K
ozd 0dj14iqs
29 Mar 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
4:01pm
8-K
6j3ey3w etva1kd8
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
60zur7op0n
5 Feb 21
Departure of Directors or Certain Officers
4:24pm
8-K
2ipm4t4u5ylc28
29 Jan 21
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
7:30am
8-K
2o2eyu8p
22 Jan 21
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19
10:41am
8-K
6dqz95s7pa
19 Jan 21
Other Events
5:24pm
8-K
za1d3rynkprrg8
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
8-K
1dfh4zxoe3r4upml4szj
11 Jan 21
Regulation FD Disclosure
6:07am
8-K
85ge2mm8
7 Jan 21
Departure of Directors or Certain Officers
4:30pm
8-K
0ylk1d
31 Dec 20
Other Events
4:37pm
8-K
rzx hcs2fl
12 Nov 20
Results of Operations and Financial Condition
6:06am
8-K
th0ug3
6 Nov 20
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
9:05am
8-K
eaw1a0izxvroc863
4 Nov 20
Humanigen Executes Licensing Agreement for Lenzilumabâ„¢ in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines
4:45pm
8-K
mt578ulziay 64
7 Oct 20
Departure of Directors or Certain Officers
4:15pm
8-K
oarkb j6ljm8w2
21 Sep 20
Other Events
8:26am
8-K
lw9tk2zin ygxhco
11 Sep 20
Departure of Directors or Certain Officers
4:43pm
8-K
eu2rre kp
4 Sep 20
Other Events
4:36pm
8-K
8ad8bflmc uh6ujff
10 Aug 20
Regulation FD Disclosure
9:08am
8-K
g0mgpeclzw0g
3 Aug 20
Departure of Directors or Certain Officers
8:30am